Cetuximab may be beneficial beyond progression in certain patients with mCRC
the ONA take:
According to new findings presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers have found that continuing second-line cetuximab beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is beneficial for patients with metastatic colorectal cancer who do not have KRAS, NRAS, BRAF, or PIK3CA gene mutations.
For the phase II study, researchers enrolled 340 patients with metastatic colorectal cancer and KRAS exon 2 wild-type tumors. All participants received first-line treatment with FOLFIRI plus cetuximab until unacceptable toxicity or disease progression. Those who experienced disease progression were then randomly assigned 1:1 to receive second-line FOLFOX plus cetuximab or FOLFOX alone.
Results showed that patients with quadruple wild-type metastatic colorectal cancer had significantly improved progression-free survival, improved overall survival, and improved response rates with the addition of second-line cetuximab. These patients were most likely to have an EGFR-dependent tumor.
The authors note that further studies are warranted to confirm these findings in a larger patient population.
Continuing second-line cetuximab beyond progression following first-line chemo and an anti-EGFR monoclonal antibody is beneficial for quadruple wild-type metastatic
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|